Fig. 1From: Regorafenib-induced renal-limited thrombotic microangiopathy: a case report and review of literaturesThe clinical course of the patient. A Bevacizumab administration during an 8-month period (Jan 2017-Aug 2017). B Regorafenib administration during a 7-month period (Nov 2018-Dec 2018, Mar 2019-Aug 2019)Back to article page